Browse DYNC1I1

Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, spindle pole
Domain PF11540 Cytoplasmic dynein 1 intermediate chain 2
PF00400 WD domain
Function

Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. The intermediate chains mediate the binding of dynein to dynactin via its 150 kDa component (p150-glued) DCNT1. May play a role in mediating the interaction of cytoplasmic dynein with membranous organelles and kinetochores.

> Gene Ontology
 
Biological Process GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0007018 microtubule-based movement
GO:0010970 transport along microtubule
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0030705 cytoskeleton-dependent intracellular transport
GO:0047496 vesicle transport along microtubule
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048193 Golgi vesicle transport
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0072384 organelle transport along microtubule
GO:0099518 vesicle cytoskeletal trafficking
Molecular Function GO:0003774 motor activity
GO:0003777 microtubule motor activity
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0030507 spectrin binding
GO:0045502 dynein binding
GO:0045503 dynein light chain binding
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0000922 spindle pole
GO:0005819 spindle
GO:0005868 cytoplasmic dynein complex
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0030286 dynein complex
GO:0035770 ribonucleoprotein granule
GO:0036464 cytoplasmic ribonucleoprotein granule
GO:0055037 recycling endosome
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04962 Vasopressin-regulated water reabsorption
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6811436: COPI-independent Golgi-to-ER retrograde traffic
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-168256: Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DYNC1I1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DYNC1I1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DYNC1I1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1050.839
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1220.908
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0930.914
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1590.768
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5050.794
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2850.899
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1650.785
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3060.767
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.030.978
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4730.0288
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.030.0271
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2270.256
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DYNC1I1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113023.1-23.10.223
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512025-250.515
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DYNC1I1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DYNC1I1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DYNC1I1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DYNC1I1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DYNC1I1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DYNC1I1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDYNC1I1
Namedynein, cytoplasmic 1, intermediate chain 1
Aliases DNCIC1; DNCI1; dynein, cytoplasmic, intermediate polypeptide 1; DH IC-1; cytoplasmic dynein intermediate cha ......
Chromosomal Location7q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DYNC1I1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.